159 related articles for article (PubMed ID: 38721331)
1. Economic and Humanistic Burden of Moderate and Severe Hemophilia A and B in Spain: Real-World Evidence Insights from the CHESS II Study.
Peral C; De Lossada Juste A; Lwoff N; Espinoza-Cámac N; Casado MÁ; Burke T; Alvir J; Thakkar S; Ferri Grazzi E
J Health Econ Outcomes Res; 2024; 11(1):122-133. PubMed ID: 38721331
[No Abstract] [Full Text] [Related]
2. Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys.
Burke T; Asghar S; O'Hara J; Sawyer EK; Li N
Orphanet J Rare Dis; 2021 Mar; 16(1):143. PubMed ID: 33743752
[TBL] [Abstract][Full Text] [Related]
3. Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B.
Burke T; Shaikh A; Ali TM; Li N; Curtis R; Garcia Diego DA; Recht M; Sannie T; Skinner M; O'Hara J
J Med Econ; 2022; 25(1):386-392. PubMed ID: 35253589
[TBL] [Abstract][Full Text] [Related]
4. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe.
Burke T; Asghar S; O'Hara J; Chuang M; Sawyer EK; Li N
Orphanet J Rare Dis; 2021 Dec; 16(1):521. PubMed ID: 34930388
[TBL] [Abstract][Full Text] [Related]
5. Disease Burden, Clinical Outcomes, and Quality of Life in People with Hemophilia A without Inhibitors in Europe: Analyses from CHESS II/CHESS PAEDs.
Chowdary P; Ofori-Asenso R; Nissen F; Grazzi EF; Aizenas M; Moreno K; Burke T; Nolan B; O'Hara J; Khair K
TH Open; 2024 Apr; 8(2):e181-e193. PubMed ID: 38628421
[No Abstract] [Full Text] [Related]
6. Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study.
Rodriguez-Santana I; DasMahapatra P; Burke T; Hakimi Z; Bartelt-Hofer J; Nazir J; O'Hara J
Orphanet J Rare Dis; 2022 Apr; 17(1):148. PubMed ID: 35379282
[TBL] [Abstract][Full Text] [Related]
7. Real-world comparative analysis of bleeding complications and health-related quality of life in patients with haemophilia A and haemophilia B.
Booth J; Oladapo A; Walsh S; O'Hara J; Carroll L; Garcia Diego DA; O'Mahony B
Haemophilia; 2018 Sep; 24(5):e322-e327. PubMed ID: 30091822
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study.
Rodriguez-Santana I; DasMahapatra P; Burke T; Hakimi Z; Bartelt-Hofer J; Nazir J; O'Hara J
Orphanet J Rare Dis; 2022 Apr; 17(1):150. PubMed ID: 35379284
[TBL] [Abstract][Full Text] [Related]
9. The humanistic and economic burden of problem joints for children and adults with moderate or severe haemophilia A: Analysis of the CHESS population studies.
Chowdary P; Nissen F; Burke T; Aizenas M; Czirok T; Dhillon H; O'Hara J
Haemophilia; 2023 May; 29(3):753-760. PubMed ID: 36897517
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual Bleed Rates.
Chen CX; Baker JR; Nichol MB
Value Health; 2017 Sep; 20(8):1074-1082. PubMed ID: 28964439
[TBL] [Abstract][Full Text] [Related]
11. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279
[TBL] [Abstract][Full Text] [Related]
12. The economic and humanistic burden of bipolar disorder in adults in the United States.
Dembek C; Mackie D; Modi K; Zhu Y; Niu X; Grinnell T
Ann Gen Psychiatry; 2023 Mar; 22(1):13. PubMed ID: 36964564
[TBL] [Abstract][Full Text] [Related]
13. The impact of bleeding event frequency on health-related quality of life and work productivity outcomes in a European cohort of adults with haemophilia A: insights from the CHESS II study.
Young L; Chen Y; Alvir J; Burke T; Ferri Grazzi E; Winburn I
Orphanet J Rare Dis; 2023 Aug; 18(1):227. PubMed ID: 37537683
[TBL] [Abstract][Full Text] [Related]
14. Emicizumab Prophylaxis in Patients with Severe Hemophilia A: Insights from A Resource Limited Country.
Borhany M; Arshad A; Qureshi H; Nadeem R; Jamal A; Ahmed Khan R
Clin Appl Thromb Hemost; 2024; 30():10760296231224357. PubMed ID: 38166474
[TBL] [Abstract][Full Text] [Related]
15. Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model.
Li N; Sawyer EK; Maruszczyk K; Guzauskas G; Slomka MT; Burke T; Martin AP; O'Hara J; Stevenson M; Recht M
J Med Econ; 2021; 24(1):363-372. PubMed ID: 33591884
[TBL] [Abstract][Full Text] [Related]
16. [Retrospectively analysis of the difference of bleeding frequency and hemophilic arthropathy between hemophilia A and hemophilia B patients].
Wang SX; Guan Y; Nie YB; Li HY; Sun BY; Wang XY; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2017 May; 38(5):404-409. PubMed ID: 28565740
[No Abstract] [Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Costs and utilization of treatment in patients with hemophilia.
Rocha P; Carvalho M; Lopes M; Araújo F
BMC Health Serv Res; 2015 Oct; 15():484. PubMed ID: 26502954
[TBL] [Abstract][Full Text] [Related]
19. Health care resource utilization and cost burden of hemophilia B in the United States.
Buckner TW; Bocharova I; Hagan K; Bensimon AG; Yang H; Wu EQ; Sawyer EK; Li N
Blood Adv; 2021 Apr; 5(7):1954-1962. PubMed ID: 33830206
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life and its associated factors among hemophilia patients: experience from Ethiopian Hemophilia Treatment Centre.
Iyar S; Gebremariam GT; Beyene DA; Gebremedhin A; Tadesse TA
J Pharm Health Care Sci; 2024 Jan; 10(1):3. PubMed ID: 38167221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
